

Revision date: 01-Apr-2015

Version: 2.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier

Material Name: PREMARIN (Conjugated Estrogens) for Injection

Trade Name: Chemical Family: PREMARIN Steroid

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet Pfizer Global Supply Pfizer Inc 235 East 42nd Street New York, NY 10017 1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture GHS - Classification

Reproductive Toxicity: Category 1A Carcinogenicity: Category 1A

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

EU Classification:

EU Indication of danger: Carcinogenic: Category 1 Toxic to reproduction: Category 1

EU Risk Phrases:

R45 - May cause cancer. R60 - May impair fertility. R61 - May cause harm to the unborn child.

Label Elements

Signal Word:	Danger
Hazard Statements:	H350 - May cause cancer
	H360 - May damage fertility or the unborn child
	May form combustible dust concentrations in air

PZ01892

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

Material Name: PREMARIN (Conjugated Estrogens) for Injection Revision date: 01-Apr-2015 Page 2 of 8

Version: 2.0

Precautionary Statements:

- P202 Do not handle until all safety precautions have been read and understood
- P281 Use personal protective equipment as required
- P308 + P313 IF exposed or concerned: Get medical attention/advice
- P405 Store locked up
- P501 Dispose of contents/container in accordance with all local and national regulations



Other Hazards Australian Hazard Classification (NOHSC):

Note:

Hazardous Substance. Non-Dangerous Goods.

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Conjugated estrogens	12126-59-9	235-199-5	Carc.Cat.1;R45 Repr.Cat.1;R60 Repr.Cat.1;R61	Carc. 1A,H350; Repr. 1A,H360FD	10

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Lactose NF, anhydrous	63-42-3	200-559-2	Not Listed	Not Listed	*
Sodium citrate	68-04-2	200-675-3	Not Listed	Not Listed	*
Simethicone	8050-81-5	Not Listed	Not Listed	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

4. FIRST AID MEASURES	
Eye Contact:	Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash off immediately with soap and plenty of water If irritation occurs or persists, get medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Most Important Symptoms and Effe Symptoms and Effects of Exposure: Medical Conditions Aggravated by Exposure:	cts, Both Acute and Delayed For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. None known
Indication of the Immediate Medical Notes to Physician:	Attention and Special Treatment Needed None
5. FIRE FIGHTING MEASURE	S
Extinguishing Media:	Extinguish fires with CO2, extinguishing powder, foam, or water.
Special Hazards Arising from the Se Hazardous Combustion Products:	ubstance or Mixture Formation of toxic gases is possible during heating or fire.
Fire / Explosion Hazards:	Not applicable
Advice for Fire-Fighters During all fire fighting activities,	wear appropriate protective equipment, including self-contained breathing apparatus.
6. ACCIDENTAL RELEASE M	EASURES
	quipment and Emergency Procedures should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Environmental Precautions Place waste in an appropriately	labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Methods and Material for Containm	ent and Cleaning Up

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Version: 2.0

Material Name: PREMARIN (Conjugated Estrogens) for Injection Revision date: 01-Apr-2015

Page	4	ot	8
------	---	----	---

Version: 2.0

7. HANDLING AND STORAGE Minimize dust generation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Conditions for Safe Storage, Including any Incompatibilities Storage Conditions: Store as directed by product packaging. Specific end use(s): Pharmaceutical drug product 8. EXPOSURE CONTROLS / PERSONAL PROTECTION **Control Parameters** Refer to available public information for specific member state Occupational Exposure Limits. **Conjugated estrogens** Pfizer OEL TWA-8 Hr: 0.15µg/m³ Simethicone Pfizer Occupational Exposure OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³) Band (OEB): **Exposure Controls Engineering Controls:** Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range. **Personal Protective** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Equipment: Hands: Wear impervious gloves as minimum protection. Eves: Wear safety glasses as minimum protection. Skin: Wear impervious protective clothing when handling this compound. **Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	lyophilised cake	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility: Water Solubility: pH: Melting/Freezing Point (°C): Boiling Point (°C): Partition Coefficient: (Method, pH Conjugated estrogens No data available Lactose NF, anhydrous No data available Sodium citrate	No data available No data available No data available. No data available No data available. I, Endpoint, Value)		

Material Name: PREMARIN (Conjugated Estrogens) for Injection Revision date: 01-Apr-2015 Page 5 of 8

Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available	
Simethicone	
No data available	
Decomposition Temperature (°C):	No data available.
Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available
Flammablity:	
Autoignition Temperature (So	olid) (°C):
Flammability (Solids):	

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity: Chemical Stability: Possibility of Hazardous Reactions	No data available Stable under normal conditions of use.
Oxidizing Properties: Conditions to Avoid: Incompatible Materials: Hazardous Decomposition Products:	No data available Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea).

Acute Toxicity: (Species, Route, End Point, Dose)

Conjugated estrogens

RatIPLD50325mg/kgMouseIVLD501740mg/kgRatOralLD50> 5000mg/kgAcute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Material Name: PREMARIN (Conjugated Estrogens) for Injection Revision date: 01-Apr-2015

Page 6 of 8

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Conjugated estrogens

Eye Irritation Rabbit Severe

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Conjugated estrogens

Embryo / Fetal Development	Rat	Subcutaneous7 mg/kg/day	LOAEL	Embryotoxicity, Fetotoxicity
Carcinogen Status:		See below		
Conjugated estrogens IARC: NTP:		Group 1 Listed		

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental relevance.
	releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.


Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Material Name: PREMARIN (Conjugated Estrogens) for Injection Revision date: 01-Apr-2015 Page 7 of 8

Version: 2.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture



Lactose NF, anhydrous	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	
EU EINECS/ELINCS List	200-559-2
Sodium citrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-675-3
Conjugated estrogens	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen, initial date 2/27/87; developmental. initial date 4/1/90
EU EINECS/ELINCS List	235-199-5
Simethicone	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Carcinogenicity-Cat.1A; H350 - May cause cancer Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.

Material Name: PREMARIN (Conjugated Estrogens) for Injection Revision date: 01-Apr-2015 Page 8 of 8

Version: 2.0

Carcinogenic: Category 1 Toxic to reproduction: Category 1	
R45 - May cause cancer. R60 - May impair fertility. R61 - May cause harm to the unborn cl Data Sources:	hild. Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.
Revision date:	01-Apr-2015 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet